Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clairafly
NCT05865886Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing 5 mg BI 1291583 with Placebo (2 arms). Primary endpoint: Occurrence of Any Treatment Emergent Adverse Events at 16 weeks. Started Apr 2024; status: completed.
02
Drugs
verducatib
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05865886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05865886.